BR112014031945A2 - derivados de cabergolina - Google Patents

derivados de cabergolina

Info

Publication number
BR112014031945A2
BR112014031945A2 BR112014031945A BR112014031945A BR112014031945A2 BR 112014031945 A2 BR112014031945 A2 BR 112014031945A2 BR 112014031945 A BR112014031945 A BR 112014031945A BR 112014031945 A BR112014031945 A BR 112014031945A BR 112014031945 A2 BR112014031945 A2 BR 112014031945A2
Authority
BR
Brazil
Prior art keywords
agonizing
receptors
compounds
methods
cabergoline
Prior art date
Application number
BR112014031945A
Other languages
English (en)
Inventor
Zhang Jian
A Armer Thomas
Original Assignee
Map Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Map Pharmaceuticals Inc filed Critical Map Pharmaceuticals Inc
Publication of BR112014031945A2 publication Critical patent/BR112014031945A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D457/00—Heterocyclic compounds containing indolo [4, 3-f, g] quinoline ring systems, e.g. derivatives of ergoline, of the formula:, e.g. lysergic acid
    • C07D457/04—Heterocyclic compounds containing indolo [4, 3-f, g] quinoline ring systems, e.g. derivatives of ergoline, of the formula:, e.g. lysergic acid with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 8
    • C07D457/06—Lysergic acid amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D457/00—Heterocyclic compounds containing indolo [4, 3-f, g] quinoline ring systems, e.g. derivatives of ergoline, of the formula:, e.g. lysergic acid
    • C07D457/04—Heterocyclic compounds containing indolo [4, 3-f, g] quinoline ring systems, e.g. derivatives of ergoline, of the formula:, e.g. lysergic acid with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 8

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

resumo patente de invenção: "derivados de cabergolina". a presente invenção refere-se a novos análogos de cabergolina e suas composições. em outras modalidades, são aqui fornecidos métodos de tratamento, prevenção ou melhora de uma variedade de distúrbios médicos tais como, por exemplo, enxaqueca e doença de parkinson, utilizando os compostos e as composições aqui descritos. em mais outras modalidades, são aqui fornecidos métodos de agonizar os receptores dopaminérgicos d2 e/ou antagonizar ou inibir a atividade dos receptores tais como os receptores de serotonina 5-ht2 utilizando os compostos e as composições aqui descritos. em mais outras modalidades, são aqui fornecidos métodos de agonizar os receptores tais como, por exemplo, o receptor de 5-ht1d e/ou 5-ht1b, sem agonizar (ou muito fracamente agonizar) o receptor de 5-ht2b utilizando os compostos e composições aqui descritos.
BR112014031945A 2012-06-22 2012-06-22 derivados de cabergolina BR112014031945A2 (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2012/043687 WO2013191704A1 (en) 2012-06-22 2012-06-22 Novel cabergoline derivatives

Publications (1)

Publication Number Publication Date
BR112014031945A2 true BR112014031945A2 (pt) 2017-06-27

Family

ID=49769156

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014031945A BR112014031945A2 (pt) 2012-06-22 2012-06-22 derivados de cabergolina

Country Status (11)

Country Link
EP (1) EP2863747A4 (pt)
JP (1) JP2015525239A (pt)
CN (1) CN104822264A (pt)
AU (1) AU2012382929A1 (pt)
BR (1) BR112014031945A2 (pt)
CA (1) CA2876321A1 (pt)
HK (1) HK1208997A1 (pt)
IL (1) IL236310A0 (pt)
RU (1) RU2014153672A (pt)
SG (1) SG11201408567PA (pt)
WO (1) WO2013191704A1 (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9657020B2 (en) * 2015-01-20 2017-05-23 Xoc Pharmaceuticals, Inc. Ergoline compounds and uses thereof
CN106866656A (zh) * 2017-02-28 2017-06-20 西南交通大学 一类麦角碱衍生物及其在预防和治疗精神疾病的用途
EP3530651A1 (en) * 2018-02-21 2019-08-28 Adamed sp. z o.o. Indole and benzimidazole derivatives as dual 5-ht2a and 5-ht6 receptor antagonists

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4526892A (en) * 1981-03-03 1985-07-02 Farmitalia Carlo Erba, S.P.A. Dimethylaminoalkyl-3-(ergoline-8'βcarbonyl)-ureas
DK338789A (da) * 1988-07-15 1990-01-16 Schering Ag 2-substituerede ergolinylurinstofderivater og fremgangsmaade til fremstilling deraf, deres anvendelse som laegemidler samt mellemprodukter til fremstilling deraf
DE3913756A1 (de) * 1989-04-21 1990-10-25 Schering Ag 8(beta)-substituierte ergoline, verfahren zu ihrer herstellung und ihre verwendung
AU680539B2 (en) * 1993-08-18 1997-07-31 Alcon Laboratories, Inc. Use of ergoline derivatives for the treatment of glaucoma
CZ287176B6 (cs) * 1997-10-03 2000-10-11 Galena A. S. Způsob přípravy ergolinových derivátů
EP1592424A1 (en) * 2003-02-05 2005-11-09 Pharmacia Italia S.p.A. Cabergoline for the prophylactic treatment of migraine
GB0307377D0 (en) * 2003-03-31 2003-05-07 Merad Pharmaceuticals Ltd Ergoline derivatives
HUP0400517A3 (en) * 2004-03-04 2006-05-29 Richter Gedeon Vegyeszet Process for producing cabergoline
EP1858894A1 (en) * 2005-03-17 2007-11-28 Synthon Argentina S.A. Improved process for making cabergoline
GB0511060D0 (en) * 2005-05-31 2005-07-06 Novartis Ag Organic compounds
EP2067780A1 (en) * 2007-12-07 2009-06-10 Axxonis Pharma AG Ergoline derivatives as selective radical scavengers for neurons
EP2385944A4 (en) * 2009-01-09 2013-06-19 Harvard College FLUORINATED COMPOUNDS AND METHODS OF USE
CN102459252A (zh) * 2009-04-15 2012-05-16 阿斯利康(瑞典)有限公司 用于治疗糖原合酶激酶3相关疾病诸如阿尔茨海默病的咪唑取代的嘧啶
AU2012355983A1 (en) * 2011-12-21 2015-01-22 Map Pharmaceuticals, Inc. Novel neuromodulatory compounds

Also Published As

Publication number Publication date
EP2863747A4 (en) 2015-12-23
JP2015525239A (ja) 2015-09-03
CA2876321A1 (en) 2013-12-27
EP2863747A1 (en) 2015-04-29
WO2013191704A1 (en) 2013-12-27
IL236310A0 (en) 2015-02-26
CN104822264A (zh) 2015-08-05
RU2014153672A (ru) 2016-08-10
HK1208997A1 (en) 2016-03-24
AU2012382929A1 (en) 2015-02-05
SG11201408567PA (en) 2015-02-27

Similar Documents

Publication Publication Date Title
BR112015028452A2 (pt) agonistas do receptor somastatina subtipo 4 (sstr4)
BR112013033339A2 (pt) análogos de fluorergolina
BR112015014964A2 (pt) novos derivados de metisergida
IN2012DN04858A (pt)
GEP20217247B (en) Indole derivatives for use in medicine
PH12014502280A1 (en) Indole and indazole compounds that activate ampk
MX2015017861A (es) Derivados de benzotiofeno como inhibidores del receptor de estrogeno.
BR112015028879A8 (pt) compostos derivados heterocíclicos, composição farmacêutica compreendendo os referidos compostos e usos dos mesmos
MX2015012850A (es) Inhibidores de la arginina metiltransferasa y usos de los mismos.
BRPI0607532A2 (pt) derivados de alcanamina de diidrobenzofuranila como agonistas de 5ht2c
BR112016005270A2 (pt) compostos de aza-piridona, composições farmacêuticas e seus usos
GEP20166483B (en) Phenyl-3-aza-bicyclo[3.1.0] hex-3-yl-methanones and the use thereof as medicament
NZ605431A (en) D2 antagonists, methods of synthesis and methods of use
BR112017015487A2 (pt) Composto; composição; método de tratamento e/ou prevenção de enxaqueca, als, doença de alzheimer, doença de parkinson, distúrbios extrapirimidais, depressão, náusea, êmese, síndrome das pernas inquietas, insônia, agressão, doença de huntington, doença cardiopulmonar, fibrogênese, hipertensão arterial pulmonar, ansiedade, dependências a drogas, distonia, parassonia ou hiperlactinemia em um indivíduo; métodos de agonização dos receptores d2, 5-ht1d, 5-ht1a e 5-ht2c, em um indivíduo; método de antagonização do receptor d3 em um indivíduo; métodos de agonização seletiva dos receptores 5 -ht1d, e 5-ht2c, método de fornecimento de atividade de antagonista funcional no receptor 5 -ht2b ou no receptor 5-ht7, ou em ambos, em um indivíduo; método de fornecimento de atividade de antagonista funcional nos receptores adrenérgicos em um indivíduo
MX358307B (es) Formulaciones farmaceuticas que comprenden antagonistas de ccr3.
BR112015014957A2 (pt) derivados de fluoroergolina e usos dos mesmos
BR112017009595A2 (pt) morfolina e 1,4-oxazepano amidas como agonistas do subtipo de receptor de somatostatina 4 (sstr4)
MX350862B (es) Acidos de piperidinil naftilacetico.
NZ706591A (en) Oxazolidin-2-one-pyrimidine derivatives
PH12016500092A1 (en) New azabenzimidazole derivatives
MY156233A (en) Disubstituted tetrahydrofuranyl compounds as antagonists of the bradykinin b1 receptor
BR112013030391A2 (pt) derivados de piperidina 3- espirocíclicos como agonistas dos receptores de grelina
BR112014031945A2 (pt) derivados de cabergolina
WO2014014794A3 (en) Mineralocorticoid receptor antagonists
BR112018073419A2 (pt) combinação, uso da combinação, método para o tratamento, composto, método para o tratamento de doença de alzheimer e composição farmacêutica

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]